Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2.
J Clin OncolAug 6, 2026 (epub)
Erin M Mobley, David R Doody, Steven D Colan et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial analyzed echocardiographic data from 895 childhood cancer survivors treated with doxorubicin, assessing the long-term effects of dexrazoxane on cardiac function. Results indicated that dexrazoxane was associated with preserved left ventricular (LV) systolic function (z-score difference 0.4) and reduced hazards of LV dysfunction after 1 and 5 years post-diagnosis.
Key findings
- Dexrazoxane was linked to a z-score difference of 0.4 in LV systolic function compared to no dexrazoxane.
- Hazards of reduced LV function were decreased to 0.58 after 1 year and 0.54 after 5 years post-diagnosis.
- The incidence of reduced LV function in high-risk patients dropped from 40 to 21.8 events/1,000 person-years.
Why it matters
Understanding the cardioprotective effects of dexrazoxane is crucial for managing long-term cardiac health in childhood cancer survivors, potentially influencing screening and treatment protocols.